Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with chemotherapy with or without bevacizumab, within its marketing authorisation for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6363
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email TACommA@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 01 December 2025 | Invitation to participate |
| 19 September 2025 - 17 October 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6363 |
| 05 July 2024 | Note - Note added to the project documents |
| 09 February 2024 | In progress. In progress |
| 22 September 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual